A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

Discover why Mirum Pharmaceuticals, Inc. stock surged 65%. Explore robust pipeline growth, revenue outlook, and analyst ...

USA: A large retrospective, propensity score–matched cohort study found that ursodeoxycholic acid (UDCA) use in patients with ...

Using electronic health record data from more than 12,000 PBC patients, investigators found that UDCA use was associated with ...

Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On December 18, 2025, Mirum Pharmaceuticals entered into a subscription agreement ...

(Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with ...

Seven weeks ago, Alison Kavanaugh made the decision to donate part of her liver to her sister, whose liver was failing from a ...

Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

The firings come one month after the company voluntarily pulled a drug from the market at the request of the Food and Drug ...

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing ...